BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen HT, Huang HL, Li YQ, Xu HM, Zhou YJ. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. World J Gastroenterol 2020; 26(16): 1901-1911 [PMID: 32390701 DOI: 10.3748/wjg.v26.i16.1901] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021;13:1442. [PMID: 33923255 DOI: 10.3390/nu13051442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Dong GM, Yu H, Pan LB, Ma SR, Xu H, Zhang ZW, Han P, Fu J, Yang XY, Keranmu A, Niu HT, Jiang JD, Wang Y. Biotransformation of Timosaponin BII into Seven Characteristic Metabolites by the Gut Microbiota. Molecules 2021;26:3861. [PMID: 34202717 DOI: 10.3390/molecules26133861] [Reference Citation Analysis]
3 Bashir A, Duseja A, De A, Mehta M, Tiwari P. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.002] [Reference Citation Analysis]
4 Wang T, Ishikawa T, Sasaki M, Chiba T. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of Porphyromonas gingivalis. Front Med (Lausanne) 2022;9:822190. [PMID: 35308549 DOI: 10.3389/fmed.2022.822190] [Reference Citation Analysis]
5 Lian C, Zhai Z, Li Z, Wang L. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chemico-Biological Interactions 2020;330:109199. [DOI: 10.1016/j.cbi.2020.109199] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Gupta M, Krishan P, Kaur A, Arora S, Trehanpati N, Singh TG, Bedi O. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. Inflamm Res 2021;70:765-76. [PMID: 34212214 DOI: 10.1007/s00011-021-01480-z] [Reference Citation Analysis]
7 Taha MM, Aneis YM, Mohamady HM, S A A, Elsayed SH. Effect of focused ultrasound cavitation augmented with aerobic exercise on abdominal and intrahepatic fat in patients with non-alcoholic fatty liver disease: A randomized controlled trial. PLoS One 2021;16:e0250337. [PMID: 33909662 DOI: 10.1371/journal.pone.0250337] [Reference Citation Analysis]
8 Hernández-Ceballos W, Cordova-Gallardo J, Mendez-Sanchez N. Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. J Clin Transl Hepatol 2021;9:227-38. [PMID: 34007805 DOI: 10.14218/JCTH.2020.00131] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, Hrabar D, Smircic Duvnjak L. New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2021;9:51-9. [PMID: 33604255 DOI: 10.14218/JCTH.2020.00057] [Reference Citation Analysis]
10 Salehi-Sahlabadi A, Sadat S, Beigrezaei S, Pourmasomi M, Feizi A, Ghiasvand R, Hadi A, Clark CCT, Miraghajani M. Dietary patterns and risk of non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:41. [PMID: 33509112 DOI: 10.1186/s12876-021-01612-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sun D, Zuo C, Huang W, Wang J, Zhang Z. Triclosan targeting of gut microbiome ameliorates hepatic steatosis in high fat diet-fed mice. J Antibiot (Tokyo) 2022. [PMID: 35440769 DOI: 10.1038/s41429-022-00522-w] [Reference Citation Analysis]
12 Hu S, Lian PP, Hu Y, Zhu XY, Jiang SW, Ma Q, Li LY, Yang JF, Yang L, Guo HY, Zhou H, Yang CC, Meng XM, Li J, Li HW, Xu T, Zhou H. The Role of IL-35 in the Pathophysiological Processes of Liver Disease. Front Pharmacol 2020;11:569575. [PMID: 33584256 DOI: 10.3389/fphar.2020.569575] [Reference Citation Analysis]